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Hepatitis B Virus Vaccine immune response in Egyptian children 15-17 
years after primary immunization; should we provide a booster dose? 
 
INTRODUCTION 
Hepatitis B virus (HBV) infection is a global public 
health problem. With approximately 350 million 
hepatitis B virus (HBV) carriers in the world, of 
whom over 600,000 die annually from hepatitis B-
associated liver disease1. Egypt is considered as a 
region of intermediate prevalence for HBV 
infection with reported figure of 4.5%2. 
In 1992, Egypt started a program of universal 
immunization in infancy in accordance with the 
WHO recommendations. The schedule adopted by 
Egyptian Ministry of Health was three doses of 
yeast-recombinant hepatitis B vaccine administered 
to all infants at 2, 4 and 6 months to coincide with 
other compulsory vaccines (Diphtheria, Tetanus, 
Pertussis and oral polio (DPT- OPV)3. 
Few Egyptian studies have evaluated the 
duration of protection of HBV vaccines after 
receiving the primary immunization. Up to our 
knowledge our study is the first to evaluate the  
 
immune status to HBV vaccine among Egyptian 
children more than 15 years after primary 
immunization. Also in this study we tried to assess 
the immunological memory to HBV vaccine by 
examining the response to a booster dose of vaccine 
for those who did not have protective serum anti-
HBs level (lower than 10 mIU/ml). 
 
METHODS 
This cross-sectional study included two hundred 
twenty five (225) healthy university students 
affiliated to different colleges in Ain Shams 
University, their ages ranged from 16-18 years. 
They were 154 males and 71 females. They were all 
documented to have received 3 doses of HBV 
vaccine at ages 2, 4, 6 months. None of them have a 
history suggestive of either chronic liver disease or 
chronic extrahepatic disease. 
All study candidates were exposed to a full 
history taking, thorough clinical examination and 
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filled up a questionnaire about the demographic 
data and risk factors for liver disease and chronic 
diseases that may affect the immune response to 
vaccine. Vaccination certificate were checked and 
receiving the full primary immunization set was 
confirmed for each study candidate. 
Serum samples were collected from the study 
candidates after signing informed consent. All 
serum samples were studied for HBV surface 
antibody level using ELISA. Those with serum 
anti-HBs higher than 10 IU/ml were considered 
immune. Others with serum anti-HBs less than 10 
IU/ml were given a booster dose (10 mcg/1.0 ml) of  
HBV vaccine [Hepatitis-B Vaccine, B.P (r-DNA), 
genetically engineered recombinant vaccine, 
VACSERA] manufactured by VACSERA under 
license of SHANTHA BIOTECHNIC. This dose was 
given to test for anamnestic reaction and HBsAb 
titer was measured again after one month.  
HB surface antigen and HB core antibodies were 
to be done for every patient who did not show a 
good anamnestic response to the booster dose to 
exclude HBV infection. 
Anti HBs antigen levels greater than 10 mIU/ml 
were considered protective4. A good anamnestic 
response was defined as serum anti-HBs antibodies 
level changing from less than 10 mIU/ml to more 




Median age of the studied population was 17.8 
years with a range of 16-18 years. Study candidates 
were born in different Egyptian governorates and 
have received their primary vaccination set in their 
place of birth. Most of the studied candidates 
(91.1%) showed serum HBsAb level below 10 
IU/ml (not protected) whereas only 20 (8.9%) had a 
protective level of serum HBsAbs. The mean serum 
HBsAb was 5.4 + 2.1 IU/ml. Those with protective 
HBsAb titer were not different in age, gender or 
social class when compared with the other group 
without protective level. Table 1 shows the 
distribution of serum HBsAbs level among the 
studied candidates before receiving a booster dose 
of HBV vaccine. 
A booster dose was given to 56 (around 25%) of 
the study candidates whose serum HBsAb was less 
than 10 mIU/ml. These candidates were randomly 
selected and were 20 males and 36 females with 
median age 17.9 + 0.2 years (range 16 – 18 years). 
HBsAb was measured one month after the booster 
dose. 
All the 56 study candidates showed good 
anamnestic response with serum HBsAb higher 
than 10 mIU/ml (protective value). Table 2 shows 
the HBsAb serum level before and one month after 
booster dose in the 56 study candidates. Age, 
gender and social class had no significant effect on 
the anamnestic response. 
 
 
Table 1. Distribution of serum HBsAbs level among the 
studied candidates before booster dose of HBV vaccine. 
 
HBsAbs level (IU/ml) Number of candidates % 
0-2 33 14.7% 
3-4 54 24% 
5-6 63 28% 
7-8 47 20.9% 
9-10 8 3.5% 




Table 2. Effect of booster dose of HBV vaccine on antibody titer among the 56 
candidates who received the booster dose. 
 
 
Total Number : 56 
Serum anti-HB surface antibody titer (mIU/ml) 
Range                       Mean + SD 
Significance 
P value 
Before booster dose 1-9                            5.46+ 2.1 <  0.0001* After booster dose 10-1000                     785+308 
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DISCUSSION 
Hepatitis B vaccination is a well-established, safe 
and effective method of conferring long-term 
protection against hepatitis B viral infections, liver 
cirrhosis and hepatocellular carcinoma (HCC) 
worldwide. It is recommended by world Health 
Organization (WHO) for all infants6. Inclusion of 
hepatitis B vaccine into national infant 
immunization programs could prevent >80% of 
HBV-related deaths7. One hundred and seventy 
nine countries have introduced a hepatitis B vaccine 
in their national infant immunization schedules by 
the end of 2010, including parts of India and the 
Sudan8. 
Neonatal HBV vaccination is the best effective 
measure for prevention of HBV infection in 
countries with intermediate to high level of HBV 
endemicity. The duration of protection induced by 
plasma-derived and recombinant vaccines against 
HBV was investigated by several authors. Even if 
there is a decline of antibody titers over time, there 
is evidence that immunological memory persists for 
at least 9–15 years after immunization9, 10. 
In our study, the seroprotection at 15-17 years 
after immunization was 8.9% of the studied 
population. Other studies for evaluation of 
immunogenicity and efficacy of HBV vaccination 
were done among Egyptian children but at shorter 
intervals from the primary immunization set. Afifi 
et al studied 245 vaccinated  children aged 6–7 
years and 9-11 years; they reported seroprotection 
in 47.5% and 39.3% of them respectively11. Also, 
Elsayed et al studied 200 vaccinated children who 
were divided into two groups. Group A, 100 child 
aged 6 years and group B, 100 child 11 years old; 
and they reported similar figures of 
seroprotection12. These two studies in addition to 
our study revealed progressive pattern of waning of 
humoral immunity to HBV in vaccinated children 
with the increase in time lapsed after the primary 
immunization set.  
Immune memory to HB vaccine has been 
studied through measuring the humoral immune 
response to a single dose of HB vaccine or in vitro 
testing for T and B cell activation5. In our study, 56 
adolescents who initially had non protective HBVs 
antibodies titer showed excellent anamnestic 
response to a booster dose with a significant 
increase in serum anti HB antibody mean from 5.46 
+2.1 to 785+308 mIU/ml. That response is similar 
to other reports 13, 14 and indicates immune memory 
to HBV vaccine.  
Based on that good anamnestic response to HBV 
vaccine in our study, we do not find any indication 
for a booster dose of HBV vaccine after finishing 
the complete HBV vaccine immunization set in 
infancy in low risk Egyptian subjects. It is worth 
mentioning that most guidelines do not indicate 
administration of a booster dose for HBV. 6, 15, 16  
In conclusion, most of the adolescents in our 
study showed non protective serum anti HBs 
antibody 17 years after finishing the primary set of 
HBV vaccine immunization in infancy. However, 
the good anamnestic response to the booster dose 
may indicate that fully vaccinated low risk subjects 
do not need a HB vaccine booster dose at 17 years 
after primary immunization. 
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